Tacrolimus and corticosteroids versus tacrolimus, corticosteroids and basiliximab for control of acute rejection in de novo liver transplant recipients: A matched analysis.

被引：0
|
作者：
Sauer, IM
Langrehr, JM
Pascher, A
Bechstein, WO
Neuhaus, P
机构：
来源：
TRANSPLANTATION | 2000年 / 69卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
212
引用
收藏
页码：S168 / S168
页数：1
相关论文
共 50 条
  • [21] Hephaistos Study Outcome on Renal Function after 12 Month Everolimus Plus Reduced Tacrolimus in De Novo Liver Transplant Recipients versus Standard Tacrolimus.
    Braun, F.
    Schemmer, P.
    Schlitt, H.
    Pascher, A.
    Klein, C.
    Neumann, U.
    Kroeger, I.
    Wimmer, P.
    Nashan, B.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 556 - 556
  • [22] Extended Release Tacrolimus Versus Conventional Tacrolimus in De Novo Orthotopic Liver Transplantation.
    Ortiz de Urbina, Jorge
    Ramon Fernandez-Ramos, J.
    Matarranz, Amaia
    Valdivieso, Andres
    Javier Bustamante-Schneider, F. C. O.
    Gastaca, Mikel
    Testillano, Milagros
    Ruiz-Ordorica, Patricia
    Ventoso, Alberto
    Gonzalez-Uriarte, Javier
    Jesus Suarez, Maria
    LIVER TRANSPLANTATION, 2011, 17 (06) : S151 - S151
  • [23] De Novo Everolimus (EVR) Versus Mycophenolate (MPA) in Kidney Transplant Recipients Receiving Tacrolimus (TAC).
    Cristelli, M.
    Felipe, C.
    Oliveira, N.
    Gusukuma, L.
    Ferreira, A.
    Sandes-Freitas, T.
    Franco, M.
    Tedesco, H.
    Medina-Pestana, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 141 - 141
  • [24] De Novo Everolimus (EVR) Versus Mycophenolate (MPA) in Kidney Transplant Recipients Receiving Tacrolimus (TAC).
    Cristelli, M.
    Felipe, C.
    Oliveira, N.
    Gusukuma, L.
    Ferreira, A.
    Sandes-Freitas, T.
    Franco, M.
    Tedesco, H.
    Medina-Pestana, J.
    TRANSPLANTATION, 2014, 98 : 141 - 141
  • [25] Everolimus in De Novo Liver Transplant Recipients To Either Minimize or Eliminate Tacrolimus - Study Design and Update
    Filipponi, F.
    De Carlis, L.
    Metselaar, H. J.
    Nevens, F.
    Saliba, F.
    Junge, G.
    LIVER TRANSPLANTATION, 2010, 16 (06) : S132 - S133
  • [26] Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids
    Hesselink, DA
    Ngyuen, H
    Wabbijn, M
    Gregoor, PJHS
    Steyerberg, EW
    van Riemsdijk, LC
    Weimar, W
    van Gelder, T
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 (03) : 327 - 330
  • [27] Population Pharmacokinetics and Pharmacogenetics of Tacrolimus in de Novo Pediatric Kidney Transplant Recipients
    Zhao, Wei
    Elie, Valery
    Roussey, Gwenaelle
    Brochard, Karine
    Niaudet, Patrick
    Deschenes, Georges
    Cochat, Pierre
    Cloarec, Sylvie
    Andre, Jean Luc
    Tsimaratos, Michel
    Bensman, Albert
    Fakhoury, May
    Jacqz-Aigrain, Evelyne
    THERAPEUTIC DRUG MONITORING, 2009, 31 (05) : 662 - 662
  • [28] Use of a once daily modified release tacrolimus regimen in de novo liver transplant recipients.
    Undre, NA
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 374 - 374
  • [29] Outcomes of African-American kidney-transplant recipients treated with sirolimus, tacrolimus, and corticosteroids
    Egidi, MF
    Gaber, AO
    TRANSPLANTATION, 2003, 75 (04) : 572 - 572
  • [30] Population Pharmacokinetics and Pharmacogenetics of Tacrolimus in De Novo Pediatric Kidney Transplant Recipients
    Zhao, W.
    Elie, V.
    Roussey, G.
    Brochard, K.
    Niaudet, P.
    Leroy, V.
    Loirat, C.
    Cochat, P.
    Cloarec, S.
    Andre, J. L.
    Garaix, F.
    Bensman, A.
    Fakhoury, M.
    Jacqz-Aigrain, E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 86 (06) : 609 - 618
12345